Zidovudine

When ATH:
J05AF01

Characteristic.

Crystalline powder from white to beige, without smell. Solubility in water at 25 ° C is 20,1 mg / ml.

Pharmacological action.
Antiviral, inhibiting HIV reverse transcriptase.

Application.

Early (with the number of T cells₄ less than 500 / mm³) and late stage of HIV infection, prevention of HIV transplacental infection of the fetus.

Contraindications.

Hypersensitivity, severe neutropenia, gipohromnaya anemia. Myopathy, hepatomegaly with steatosis.

Pregnancy and breast-feeding.

Category actions result in FDA - C. (The study of reproduction in animals has revealed adverse effects on the fetus, and adequate and well-controlled studies in pregnant women have not held, However, the potential benefits, associated with drugs in pregnant, may justify its use, in spite of the possible risk.)

Side effects.

Myelosuppression (anemia, neutropenia, leukopenia), anorexia, vomiting, abdominal pain, dyspepsia, fever, headache, insomnia, weakness, paraesthesia, myalgia, rash.

Cooperation.

Increases concentration of fluconazole. Ganciclovir cytostatics and increase the risk of haematological disorders. The level of zidovudine in the body increases against the backdrop of probenecid (blockade urinary excretion).

Dosing and Administration.

Inside. Adults, initial dose is on 200 mg every 4 no (1200 mg / day). The range of dosages is 500-1500 mg/day. Maintenance dose - 1000 mg per day for 4-5 techniques.

Precautions.

It is recommended to study blood every 2 weeks for the first 3 months of treatment, and then — at least 1 once a month (especially in patients with impaired bone marrow function). In case of deterioration of hematological parameters requires a reduction of dose or discontinuation of treatment.

Cooperation